Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2021-03-04 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰会计师事务所募集资金存放与使用情况鉴证报告
Audit Report / Information Classification · 100% confidence The document is titled as a "募集资金存放与使用情况鉴证报告" which translates to "Verification Report on the Deposit and Use of Raised Funds" for the year ending December 31, 2020. It is issued by an accounting firm (Ernst & Young Hua Ming LLP) and includes detailed information about the company's fundraising proceeds, their deposit, usage, and compliance with regulatory requirements from the China Securities Regulatory Commission and Shanghai Stock Exchange. The document contains an auditor's verification opinion on the special report prepared by the company's board regarding the use of raised funds. This type of report is a standalone audit-related verification report focused on the management and use of capital raised by the company, not a full annual report or earnings release. It is not a simple announcement or certification but a detailed audit verification report. Therefore, it fits the category of Audit Report / Information (AR). FY 2020
2021-03-04 Chinese
百奥泰非经营性资金占用专项鉴证报告
Audit Report / Information Classification · 95% confidence The document is a specialized statement regarding non-operating fund occupation and other related party fund transactions for the year 2020 by 百奥泰生物制药股份有限公司. It is prepared by Ernst & Young Hua Ming LLP, a registered accounting firm, and references audited financial statements for the year ended December 31, 2020. The document includes detailed financial data and explanations related to these specific financial matters, and it is signed by certified public accountants. It is not a full annual report (10-K) but a standalone audit-related report focusing on a specific financial issue. The document length is 9458 characters, which is substantial and contains actual financial data and audit commentary. Therefore, it fits the definition of an Audit Report / Information (AR) rather than a general Annual Report or a Regulatory Filing. It is not an announcement or certification only, but a detailed audit-related disclosure. FY 2020
2021-03-04 Chinese
百奥泰2020年年度股东大会通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2020 Annual General Meeting (AGM) of 百奥泰生物制药股份有限公司, including details on the meeting date, voting methods, agenda items, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather the announcement and procedural information related to the AGM. The document length is 4057 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2021-03-04 Chinese
百奥泰关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 百奥泰生物制药股份有限公司 regarding the use of temporarily idle raised funds for cash management. It details the board meeting resolutions, investment purpose, risk control measures, and opinions from independent directors and the supervisory board. The document does not contain financial statements or substantive financial data but rather describes the company's plan and approval to use idle funds for low-risk financial products. It is a regulatory announcement about financing activities related to the company's capital raised from an IPO and its management, not a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is about 5400 characters, which is sufficient for a detailed announcement but not a full report like an Annual or Interim Report.
2021-03-04 Chinese
中国国际金融股份有限公司关于百奥泰生物制药股份有限公司2020年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a special verification report on the storage and use of raised funds for the year 2020 by 百奥泰生物制药股份有限公司, prepared by 中国国际金融股份有限公司 as the sponsor institution. It references regulatory guidelines related to the management and use of raised funds, details the amount of funds raised, their usage, storage, and compliance with regulations. It includes detailed financial figures about the raised funds, their allocation, and usage status, as well as auditor's verification and sponsor's opinions. The document is a standalone audit/verification report focused specifically on the raised funds usage and compliance, not a full annual report or earnings release. It is not a mere announcement or certification but contains substantive financial and compliance information. Therefore, it fits the category of Audit Report / Information (AR). FY 2020
2021-03-04 Chinese
2020年会计师事务所对公司内部控制的审计报告
Audit Report / Information Classification · 95% confidence The document is titled "内部控制审计报告" which translates to "Internal Control Audit Report". It is issued by Ernst & Young Hua Ming LLP, a recognized accounting firm, and dated December 31, 2020. The content includes detailed evaluation of the company's internal control over financial reporting, assessment of control deficiencies, and audit opinions on the effectiveness of internal controls. It references auditing standards and internal control frameworks, and contains no indication that it is an announcement or a brief summary. The document length is substantial (15,000 characters), indicating it is a full report rather than a short announcement. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal control audits, excluding full annual reports. Therefore, the document should be classified as AR with high confidence. FY 2020
2021-03-04 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.